Laquinimod sodium is under clinical development by Active Biotech and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Laquinimod sodium’s likelihood of approval (LoA) and phase transition for Crohn’s Disease (Regional Enteritis) took place on 26 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Laquinimod sodium Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Laquinimod sodium overview

Laquinimod sodium (ABR-215062) is under development for the treatment of Crohn's disease, non-infectious non-anterior uveitis and wet age-related macular degeneration. It is an orally administered immunomodulatory compound. Laquinimod targets nuclear factor kappa B and Aryl Hydrocarbon Receptor (AHR). It was also under development for relapsing-remitting multiple sclerosis, Huntington disease, systemic lupus erythematosus patients with lupus arthritis, primary progressive multiple sclerosis, lupus nephritis and relapsing-remitting multiple sclerosis (RRMS).

Active Biotech overview

Active Biotech is a biotechnology company that focuses on the development of therapeutics in the field of cancer, inflammatory eye disorders and neurodegenerative diseases. The company’s pipeline products include naptumomab for the treatment of solid tumors and lung cancer; tasquinimod for multiple myeloma; and laquinimod for Uveitis. The portfolio comprises of antibody-based immunotherapy and small, orally active immunomodulatory molecules. It has partnerships with NeoTX Therapeutics Ltd and with the Perelman School of Medicine, University of Pennsylvania. The company’s products have patents and patent applications in markets of the US, Japan, and Europe. Active Biotech is headquartered in Lund, Sweden.

Quick View Laquinimod sodium LOA Data

Report Segments
  • Innovator
Drug Name
  • Laquinimod sodium
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Immunology
  • Musculoskeletal Disorders
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.